Clinical trial
A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
NCT00104143 · Hoffmann-La Roche, Industry · Withdrawn
Key facts
| NCT number | NCT00104143 |
|---|---|
| Title | A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis. |
| Official title | A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | A4I Antagonist |
| Enrollment | 0 |
| Start date | Oct 1, 2007 |
| First posted | Feb 24, 2005 |
| Last update posted | Aug 24, 2016 |
| Countries | Bulgaria, Canada, Czechia, Germany, Poland, Russia, Slovakia, Spain, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: